Rehabilitation program for immune-related heart muscle problems
Part of Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a special rehabilitation program, including traditional Chinese medicine, for people who have had heart muscle inflammation caused by cancer immunotherapy (called immune checkpoint inhibitors). It aims to help you recover and feel better after this side effect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with cancer (confirmed by biopsy or other tests).
- You have had heart muscle inflammation caused by immunotherapy (a type of cancer treatment that boosts your immune system).
- A team of doctors has confirmed you have recovered enough to start rehabilitation.
- You meet the traditional Chinese medicine pattern of 'Yangqi deficiency with phlegm and blood stasis' (which means your body's vital energy is low and there are blockages).
- You are generally able to care for yourself (score over 60 on a functional scale) and expected to live more than 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how to monitor and help patients who have had heart problems as a side effect of cancer immunotherapy. If you have recovered from such a heart issue, this program may support your heart health and overall recovery during and after cancer treatment.
This research tracks outcomes for cancer patients who developed heart inflammation (myocarditis) while receiving immune checkpoint inhibitor therapy. By studying survival patterns, researchers hope to better understand how to manage this serious side effect and improve care for future patients.
This study looks for specific markers in the blood that can help doctors better understand and treat heart inflammation (myocarditis) caused by immunotherapy in people with lung cancer. If you join, you will help find ways to improve care for other patients.
This study looks at genetic factors that may affect the risk of heart inflammation (myocarditis) caused by immune checkpoint inhibitors (ICIs), a type of cancer immunotherapy. It aims to find out if your genes make you more likely to develop this side effect.
This study looks at reports from large health databases to find out if certain cancer drugs (checkpoint inhibitors) cause heart problems. It aims to understand which patients have a higher risk, which may help doctors watch for heart issues in the future.
This study watches heart health in people starting immunotherapy (a cancer treatment that boosts the immune system) by checking blood samples for heart-related markers. It aims to find early signs of heart problems so they can be managed sooner.
Hear when a new Immune Checkpoint Inhibitors Related Myocarditis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.